ผลของ Iron Sucrose ทางหลอดเลือดดำในผู้ป่วยหัวใจล้มเหลวที่ขาดธาตุเหล็ก: การทดลองแบบสุ่มที่มีกลุ่มควบคุม

Warawut Mateesiriwat

Authors

Warawut Mateesiriwat Department ofMedicine, Samutsakhon Hospital, Samutsakhon Province 74000

Keywords:

Left Ventricular Ejection Fraction, Quality of Life, Iron Deficiency, Heart Failure, Iron Sucrose

Abstract

Objectives: To evaluate the effects of IV Iron Sucrose on iron status, left ventricular ejection fraction (LVEF), and clinical outcomes in patients with heart failure.

Methods: This randomized, open-label, outcome assessor-blinded controlled trial included 60 outpatients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency. Participants were randomized into two groups (n=30 per group): the intervention group received IV Iron Sucrose 200 mg, and the control group received standard care. Over a 24-week follow-up period, the primary outcomes measured were LVEF, iron status (ferritin and TSAT), and hemoglobin levels. Secondary outcomes included NYHA functional class, quality of life (MLHFQ score), and HF-related hospitalization rates. Data were analyzed using independent t-test, Mann-Whitney U test, and chi-square test.

Results: At 24 weeks, the Iron Sucrose group demonstrated significantly greater improvements compared to the control group: LVEF increased [Median (IQR) = 36.55% (29.50–41.00) vs. 30.50% (25.00–35.00); p=0.002], ferritin levels increased [251.50 ng/mL (221.00–298.40) vs. 68.05 ng/mL (54.00–76.00); p< 0.001], TSAT increased [25.75% (20.00–29.00) vs. 18.00% (16.00–20.00); p=0.002], and hemoglobin levels increased [14.00 g/dL (13.10–15.00) vs. 12.95 g/dL (12.00–13.80); p=0.001]. The treatment group also showed improved NYHA functional class (p<0.001), better quality of life(MLHFQ) (p=0.001), and reduced hospitalization rates (p=0.007).

Conclusions: IV Iron Sucrose significantly improves cardiac function, quality of life, and reduces hospital readmissions.

References

Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J. 2020;5:15. doi: 10.21037/amj.2020.03.03.

Chong B, Jayabaskaran J, Jauhari SM, Chan SP, Goh R, Kueh MTW, et al. Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur J Prev Cardiol. 2025;32(11):1001–15. doi: 10.1093/eurjpc/zwae281.

Statista. Number of patients with heart diseases in Thailand from 2013 to 2022 (per 100,000 population) [Internet]. Hamburg: Statista; 2024 [cited 2026 Feb 22]. Available from: https://www.statista.com/statistics/1402687/thailand-number-of-heart-disease-patients/

von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. Iron deficiency in heart failure: an overview. JACC Heart Fail. 2019;7(1):36–46. doi: 10.1016/j.jchf.2018.07.015.

Köseoğlu FD, Özlek B. Anemia and iron deficiency predict all-cause mortality in patients with heart failure and preserved ejection fraction: 6-year follow-up study. Diagnostics (Basel). 2024;14(2):209. doi: 10.3390/diagnostics14020209.

Jiampo P, Boonyapiphat T, Torpongpun A, Senthong V, Pongmesa T, Taepanich N, et al. A retrospective study of characteristics and burden of heart failure in Thailand: an interim analysis. Eur Heart J. 2023;44 (Suppl 1): ehac779.038. doi: 10.1093/eurheartj/ ehac779.038.

Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019;380(5):447–58. doi: 10.1056/NEJMoa1810742.

สมาคมแพทย์โรคหัวใจแห่งประเทศไทย ในพระบรมราชูปถัมภ์. แนวทางเวชปฏิบัติเพื่อการวินิจฉัยและการดูแลรักษาผู้ป่วยภาวะหัวใจล้มเหลว พ.ศ. 2562. พิมพ์ครั้งที่ 1. สมุทรปราการ: ห้างหุ้นส่วนจำกัด เนคสเตป ดีไซน์; 2562.

Drozd M, Jankowska EA, Banasiak W, Ponikowski P. Iron therapy in patients with heart failure and iron deficiency: review of iron preparations for practitioners. Am J Cardiovasc Drugs. 2017;17(3):183–201. doi: 10.1007/s40256-016-0211-2.

Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50(17):1657–65. doi: 10.1016/j.jacc.2007.07.029.

Toblli JE, Di Gennaro F, Rivas C. Changes in echocardiographic parameters in iron deficiency patients with heart failure and chronic kidney disease treated with intravenous iron. Heart Lung Circ. 2015;24(7):686–95. doi: 10.1016/j.hlc.2014.12.161.

Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008;51(2):103-12. doi: 10.1016/ j.jacc.2007.09.036.

Beck-da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, de Albuquerque D, et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol. 2013;168(4):3439–42. doi: 10.1016/j.ijcard.2013.04.181.

Ambrosy AP, von Haehling S, Kalra PR, Court E, Bhandari S, McDonagh T, et al. Safety and efficacy of intravenous ferric derisomaltose compared to iron sucrose for iron deficiency anemia in patients with chronic kidney disease with and without heart failure. Am J Cardiol. 2021;152:138–45. doi: 10.1016/j.amjcard.2021.04.042.

Alnuwaysir RIS, Hoes MF, van Veldhuisen DJ, van der Meer P, Grote Beverborg N. Iron deficiency in heart failure: mechanisms and pathophysiology. J Clin Med. 2021;11(1):125. doi: 10.3390/jcm11010125.

Martens P. The effect of iron deficiency on cardiac function and structure in heart failure with reduced ejection fraction. Card Fail Rev. 2022;8:e06. doi: 10.15420/cfr. 2021.26.

Hoes MF, Grote Beverborg N, Kijlstra JD, Kuipers J, Swinkels DW, Giepmans BNG, et al. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. Eur J Heart Fail. 2018;20(5):910–9. doi: 10.1002/ejhf.1154.

Awad AK, Abdelgalil MS, Gonnah AR, Mouffokes A, Ahmad U, Awad AK, et al. Intravenous iron for acute and chronic heart failure with reduced ejection fraction (HFrEF) patients with iron deficiency: an updated systematic review and meta-analysis. Clin Med (Lond). 2024;24(3):100211. doi: 10.1016/j.clinme.2024.100211.

Yamani N, Ahmed A, Gosain P, Fatima K, Shaikh AT, Qamar H, et al. Effect of iron supplementation in patients with heart failure and iron deficiency: a systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2021;36:100871. doi: 10.1016/j.ijcha. 2021.100871.

Pereira GAR, Beck-da-Silva L. Iron deficiency in heart failure with reduced ejection fraction: pathophysiology, diagnosis and treatment. Arq Bras Cardiol. 2022;118(3):646–54. doi: 10.36660/abc.20201257.

Pollock RF, Kalra PA, Kalra PR, Ahmed FZ. A systematic review, meta-analysis, and indirect comparison of blindly adjudicated cardiovascular event incidence with ferric derisomaltose, ferric carboxymaltose, and iron sucrose. Adv Ther. 2022;39(10):4678–91. doi: 10.1007/s12325-022-02242-x.

Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895-904. doi: 10.1016/S0140-6736(20)32339-4.

McEwan P, Harrison C, Binnie R, Lewis RD, Cohen-Solal A, Lund LH, et al. Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation. Eur J Heart Fail. 2023;25(3):389–98. doi: 10.1002/ejhf.2788.